Provided is a modified matrix protein of a vesicular stomatitis virus, wherein the protein has amino acid substitutions at position 21, position 51, position 111 and position 221. Further provided are an attenuated strain of the vesicular stomatitis virus producing the modified matrix protein, a composition containing the attenuated strain, and uses thereof in preparing a drug for killing abnormally proliferating cells, inducing and promoting antitumor immune response, or eliminating immunosuppression in a microenvironment of a tumor tissue.

Provided is a modified matrix protein of a vesicular stomatitis virus, wherein the protein has amino acid substitutions at position 21, position 51, position 111 and position 221. Further provided are an attenuated strain of the vesicular stomatitis virus producing the modified matrix protein, a composition containing the attenuated strain, and uses thereof in preparing a drug for killing abnormally proliferating cells, inducing and promoting antitumor immune response, or eliminating immunosuppression in a microenvironment of a tumor tissue.

The invention relates to vectors based on a virus from the order Mononegavirales, and in particular a rabies virus. More specifically, it relates to a rabies virus vector which, having transfected a target cell, is switchable between replication-competent and replication-incompetent forms. Amongst other applications, the invention avoids the cytotoxicity associated with current vectors based on rabies virus.

The invention relates to vectors based on a virus from the order Mononegavirales, and in particular a rabies virus. More specifically, it relates to a rabies virus vector which, having transfected a target cell, is switchable between replication-competent and replication-incompetent forms. Amongst other applications, the invention avoids the cytotoxicity associated with current vectors based on rabies virus.

An antiviral peptide provided by the present invention includes: (1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (2) an amino acid sequence that functions as a cell penetrating peptide (CPP).

An antiviral peptide provided by the present invention includes: (1) the signal sequence of a glycoprotein encoded for by the G gene of the vesicular stomatitis virus (VSV), or the signal sequence of hemagglutinin encoded for by the HA gene of the influenza A or influenza B virus, or a modified amino acid sequence formed by conservative substitution of 1, 2 or 3 amino acid residues in any of these signal sequences; and (2) an amino acid sequence that functions as a cell penetrating peptide (CPP).

Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S.sub.1, wherein T is a target binding domain and S.sub.1 is a stalk portion. The stalk portion may comprise a variant Fe domain. The stalk portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S.sub.1 may be incorporated into a viral particle to assist with targeting such particles to a specific cell type. Also provided for herein are compositions comprising the same, and methods of using the same.

Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S.sub.1, wherein T is a target binding domain and S.sub.1 is a stalk portion. The stalk portion may comprise a variant Fe domain. The stalk portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S.sub.1 may be incorporated into a viral particle to assist with targeting such particles to a specific cell type. Also provided for herein are compositions comprising the same, and methods of using the same.

The present disclosure provides methods of treating cancer using complementary transgenic oncolytic viruses and genetically engineered CAR T cells. In one embodiment, the oncolytic virus comprises nucleotide sequences encoding CD19, or CD19 and IL-12, and the genetically engineered T cells express a chimeric antigen receptor that recognizes CD19.

The present disclosure provides methods of treating cancer using complementary transgenic oncolytic viruses and genetically engineered CAR T cells. In one embodiment, the oncolytic virus comprises nucleotide sequences encoding CD19, or CD19 and IL-12, and the genetically engineered T cells express a chimeric antigen receptor that recognizes CD19.